Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemab Therapeutics HoldingsCOAG +3.48%11 Current Ratio is 18.03 as of Dec. 2025, which is 13% above its 10-year median of 15.99. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Hemab Therapeutics Holdings ranks better than 90.29% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Hemab Therapeutics Holdings's current ratio for the quarter that ended in Dec. 2025 was 18.03.
Hemab Therapeutics Holdings has a current ratio of 18.03. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Hemab Therapeutics Holdings's Current Ratio or its related term are showing as below:
COAG'
s Current Ratio Range Over the Past 10 Years
Min: 13.95 Med: 15.99 Max: 18.03
Current: 18.03
During the past 2 years, Hemab Therapeutics Holdings's highest Current Ratio was 18.03. The lowest was 13.95. And the median was 15.99.
COAG's Current Ratio is ranked better than 90.29% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs COAG: 18.03
Hemab Therapeutics Holdings (NAS:COAG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Hemab Therapeutics Holdings Current Ratio Related Terms
Hemab Therapeutics Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings Current Ratio Chart
Hemab Therapeutics Holdings Annual Data
Trend
Dec24
Dec25
Current Ratio
13.95
18.03
Hemab Therapeutics Holdings Semi-Annual Data
Dec24
Dec25
Current Ratio
13.95
18.03
COAG vs ZLAB, SLS, IOVA: Current Ratio Comparison
For the Biotechnology subindustry, Hemab Therapeutics Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemab Therapeutics Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Hemab Therapeutics Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings (COAG) has a Current Ratio of 18.03 as of Dec. 2025. This is 13% above median its historical median of 15.99. Over the past decade, Hemab Therapeutics Holdings' Current Ratio has ranged from 13.95 to 18.03. According to the industry distribution chart, Hemab Therapeutics Holdings ranks #137 out of 1411 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Hemab Therapeutics Holdings' Current Ratio too high?
Hemab Therapeutics Holdings' current Current Ratio of 18.03 is 13% above median its 10-year median of 15.99. Over the past 10 years, this metric has ranged from a low of 13.95 to a high of 18.03. The Biotechnology industry median Current Ratio is 3.85. Hemab Therapeutics Holdings' value of 18.03 is 368.3% above this industry median. Based on the distribution chart, Hemab Therapeutics Holdings ranks #137 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Current Ratio compare to ZLAB and SLS?
According to the Biotechnology industry distribution chart, Hemab Therapeutics Holdings ranks #137 out of 1411 companies for Current Ratio. This places Hemab Therapeutics Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.85. Hemab Therapeutics Holdings' value of 18.03 is 368.3% above this benchmark. Historically, Hemab Therapeutics Holdings' own Current Ratio has ranged from 13.95 to 18.03 over the past decade. While the company's 10-year median is 15.99 vs. the industry median of 3.85, Hemab Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemab Therapeutics Holdings's current Current Ratio of 18.03 is 368.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemab Therapeutics Holdings's current Current Ratio is 18.03, which is 13% above median its own 10-year median of 15.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Current Ratio of 18.03. The current Current Ratio is 18.03, which is 13% above median its 10-year median of 15.99 and 368.3% above the Biotechnology industry median of 3.85. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Current Ratio is 18.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score
Get the complete analysis for COAG
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COAG has been successfully added to your 
